



vigabatrin 100mg and 500mg soluble tablets (Kigabeq[®])

Veriton Pharma

07 May 2021

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

vigabatrin (Kigabeq[®]) is accepted for restricted use within NHSScotland.

Indication under review: In infants and children from 1 month to less than 7 years of age for:

- Treatment in monotherapy of infantile spasms (West's syndrome).
- Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated.

SMC restriction: patients in whom other formulations of vigabatrin are not suitable.

Vigabatrin 500mg soluble tablets are considered bioequivalent to vigabatrin 500mg granules for oral solution. Vigabatrin soluble tablets are more expensive than vigabatrin granules for oral solution. Overall net budget impact is likely to be small.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 16 April 2021.

**Chairman
Scottish Medicines Consortium**